July 13, 2021

Kephera Diagnostics launches CLIA test for quantitative antibody response to COVID-19 vaccination

Kephera Diagnostics announced today the launch of a quantitative test to measure the level of antibodies elicited by vaccination against COVID-19, as well as by COVID-19 infection. The test will be available as a service through Kephera’s CLIA-certified laboratory.

Kephera’s COVI-QUANT™ test provides an objective measurement of antibody levels based on an international standard developed by the World Health Organization. The test currently uses a standard blood sample, with a less-invasive finger prick dried blood spot option coming soon.

Kephera Diagnostics is an MLSC Internship Challenge host company. Additionally, the company was awarded funding through the Center’s Accelerating Coronavirus Testing Solutions program which supports projects focused on two core areas: accelerating the development of at-home or point-of-care testing methods that are simpler and faster, and new and innovative solutions that address existing supply chain bottlenecks.